Cost-effectiveness of the National Diabetes Prevention Program: A Real-world, 2-Year Prospective Study
Main finding · 2-year total direct medical costsResult — go to the resultAverage reduction $4,552 2020 U.S. dollars 95% CI −13,231 to 2,014Authors' conclusion
In this real-world population with prediabetes, enrollment in the NDPP was likely to provide cost savings.
Study context
- Population
- Adults with prediabetes in a large workforce with employer-sponsored health insurance
- Participants
- 5,948 adults
- Exposure
- National Diabetes Prevention Program (NDPP) enrollment vs nonenrollment
- NDPPn = 575
- Nonenrolleesn = 5,373reference
- Outcome
- 2-year total direct medical costs
- Follow-up
- 2 years
Methodological detailsreal-world, difference-in-differences analyses, propensity score weighting, multiple imputation, bootstrapping, health care sector perspective, costs and quality-adjusted life-years (QALYs) discounted at 3% annually, 2020 U.S. dollars
- Real-world
- Difference-in-differences analyses
- Propensity score weighting
- Multiple imputation
- Bootstrapping
- Health care sector perspective
- Costs and QALYs discounted at 3% annually
- 2020 U.S. dollars
Main finding
As reported in the abstract
Average reduction
$4,552 2020 U.S. dollars
95% CI −13,231 to 2,014
Observational data: associations, not effects.
Further findings
EQ-5D-5L utility scores and QALYs · 2 years
- No difference in EQ-5D-5L utility scores at 2 years or QALYs gained over 2 years, enrollees vs nonenrollees
Uncertainty analyses · 2 years
- Probability of saving money with NDPP enrollment
- 88%
- Probability of being cost-effective at willingness-to-pay threshold of $100,000 per QALY gained
- 84%
Original publication
Cost-effectiveness of the National Diabetes Prevention Program: A Real-world, 2-Year Prospective Study. Diabetes Care. Published 20 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →